Comparison Overview

Bristol Myers Squibb

VS

PT Kalbe Farma, Tbk

Bristol Myers Squibb

3401 Princeton Pike, None, Lawrence Township, NJ, US, 08648
Last Update: 2025-12-09
Between 800 and 849

At Bristol Myers Squibb, we work every day to transform patients’ lives through science. That work inspires some of the most interesting, meaningful, and life-changing careers you’ll experience. Join us and pursue innovative ideas alongside some of the brightest minds in biopharma, collaborating with a team rich in diversity of experiences, and perspectives. We have built a sustainable pipeline of potential therapies and are leveraging translational medicine and data analytics to understand how we can deliver the right medicine to the right patient, at the right time, to achieve the best outcome. Whether in a scientific, business or supporting function, a career at BMS means you’ll be inspired every day to grow and thrive through opportunities that are uncommon in scale and scope. Here, you’ll be on the cutting edge of powerful innovation in oncology, hematology, immunology, cardiovascular disease, and fibrosis, with colleagues united in the mission to help patients. Through the Bristol Myers Squibb Foundation, we also promote health equity and seek to improve health outcomes of populations disproportionately affected by serious diseases and conditions. Our mission is to give new hope to help patients prevail over serious disease – it drives everything we do. Review our Social Media Community Guidelines at: https://www.bms.com/social-media-community-guidelines.html

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 38,467
Subsidiaries: 0
12-month incidents
0
Known data breaches
0
Attack type number
1

PT Kalbe Farma, Tbk

KALBE Building, Jl. Letjen Suprapto Kav 4, Jakarta, DKI Jakarta, ID, 10510
Last Update: 2025-12-09
Between 750 and 799

Established in 1966, PT Kalbe Farma Tbk. (“the Company” or “Kalbe”) has gone a long way from its humble beginnings as a garage-operated pharmaceutical business in North Jakarta. It has expanded by strategic acquisitions of pharmaceutical companies, building a leading brand positioning and reaching to international markets to transform itself into an integrated consumer health and nutrition enterprise to promote its mission to improve health for a better life. Kalbe expands its business interests and transformed itself to become a provider of an integrated healthcare solution through its 4 business divisions: the Prescription Pharmaceutical Division, Consumer Health Division, Nutritionals Division and Distribution and Logistics Division. These business divisions manage an extensive portfolio of prescription pharmaceuticals and OTC drugs, energy drink and nutrition products, as well as a robust distribution arm serving over one million outlets across Indonesia’s vast archipelago. In the international market, the Company has established its footprint in ASEAN countries, Nigeria, and South Africa, positioning Kalbe as a national pharmaceutical company with a competitive edge in the export market. Kalbe Farma has established a robust research and development activities in leading edge generic drug formulation and continuous development of innovative consumer and nutritional products. Through strategic alliances with international partners, Kalbe have also started to support several successful research and development venture working on cancer drugs, stem cells and biotechnology research. With 17,000 employees, Kalbe Farma is the largest healthcare provider in Indonesia, with unrivaled marketing, branding, distribution, financial strength and research and development expertise. Kalbe Farma is also the largest publicly-listed pharmaceutical company in Southeast Asia, commanding a market capitalization of Rp71.0 trillion and sales turnover Rp21.0 trillion by end of 2018.

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 12,334
Subsidiaries: 1
12-month incidents
0
Known data breaches
0
Attack type number
0

Compliance Badges Comparison

Security & Compliance Standards Overview

https://images.rankiteo.com/companyimages/bristol-myers-squibb.jpeg
Bristol Myers Squibb
ISO 27001
ISO 27001 certification not verified
Not verified
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
GDPR
GDPR certification not verified
Not verified
PCI DSS
PCI DSS certification not verified
Not verified
HIPAA
HIPAA certification not verified
Not verified
https://images.rankiteo.com/companyimages/pt-kalbe-farma.jpeg
PT Kalbe Farma, Tbk
ISO 27001
ISO 27001 certification not verified
Not verified
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
GDPR
GDPR certification not verified
Not verified
PCI DSS
PCI DSS certification not verified
Not verified
HIPAA
HIPAA certification not verified
Not verified
Compliance Summary
Bristol Myers Squibb
100%
Compliance Rate
0/4 Standards Verified
PT Kalbe Farma, Tbk
0%
Compliance Rate
0/4 Standards Verified

Benchmark & Cyber Underwriting Signals

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for Bristol Myers Squibb in 2025.

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for PT Kalbe Farma, Tbk in 2025.

Incident History — Bristol Myers Squibb (X = Date, Y = Severity)

Bristol Myers Squibb cyber incidents detection timeline including parent company and subsidiaries

Incident History — PT Kalbe Farma, Tbk (X = Date, Y = Severity)

PT Kalbe Farma, Tbk cyber incidents detection timeline including parent company and subsidiaries

Notable Incidents

Last 3 Security & Risk Events by Company

https://images.rankiteo.com/companyimages/bristol-myers-squibb.jpeg
Bristol Myers Squibb
Incidents

Date Detected: 5/2023
Type:Cyber Attack
Attack Vector: Malware
Blog: Blog
https://images.rankiteo.com/companyimages/pt-kalbe-farma.jpeg
PT Kalbe Farma, Tbk
Incidents

No Incident

FAQ

Bristol Myers Squibb company demonstrates a stronger AI Cybersecurity Score compared to PT Kalbe Farma, Tbk company, reflecting its advanced cybersecurity posture governance and monitoring frameworks.

Bristol Myers Squibb company has historically faced a number of disclosed cyber incidents, whereas PT Kalbe Farma, Tbk company has not reported any.

In the current year, PT Kalbe Farma, Tbk company and Bristol Myers Squibb company have not reported any cyber incidents.

Neither PT Kalbe Farma, Tbk company nor Bristol Myers Squibb company has reported experiencing a ransomware attack publicly.

Neither PT Kalbe Farma, Tbk company nor Bristol Myers Squibb company has reported experiencing a data breach publicly.

Bristol Myers Squibb company has reported targeted cyberattacks, while PT Kalbe Farma, Tbk company has not reported such incidents publicly.

Neither Bristol Myers Squibb company nor PT Kalbe Farma, Tbk company has reported experiencing or disclosing vulnerabilities publicly.

Neither Bristol Myers Squibb nor PT Kalbe Farma, Tbk holds any compliance certifications.

Neither company holds any compliance certifications.

PT Kalbe Farma, Tbk company has more subsidiaries worldwide compared to Bristol Myers Squibb company.

Bristol Myers Squibb company employs more people globally than PT Kalbe Farma, Tbk company, reflecting its scale as a Pharmaceutical Manufacturing.

Neither Bristol Myers Squibb nor PT Kalbe Farma, Tbk holds SOC 2 Type 1 certification.

Neither Bristol Myers Squibb nor PT Kalbe Farma, Tbk holds SOC 2 Type 2 certification.

Neither Bristol Myers Squibb nor PT Kalbe Farma, Tbk holds ISO 27001 certification.

Neither Bristol Myers Squibb nor PT Kalbe Farma, Tbk holds PCI DSS certification.

Neither Bristol Myers Squibb nor PT Kalbe Farma, Tbk holds HIPAA certification.

Neither Bristol Myers Squibb nor PT Kalbe Farma, Tbk holds GDPR certification.

Latest Global CVEs (Not Company-Specific)

Description

NXLog Agent before 6.11 can load a file specified by the OPENSSL_CONF environment variable.

Risk Information
cvss3
Base: 8.1
Severity: HIGH
CVSS:3.1/AV:L/AC:H/PR:N/UI:N/S:C/C:H/I:H/A:H
Description

uriparser through 0.9.9 allows unbounded recursion and stack consumption, as demonstrated by ParseMustBeSegmentNzNc with large input containing many commas.

Risk Information
cvss3
Base: 2.9
Severity: HIGH
CVSS:3.1/AV:L/AC:H/PR:N/UI:N/S:U/C:N/I:N/A:L
Description

A vulnerability was detected in Mayan EDMS up to 4.10.1. The affected element is an unknown function of the file /authentication/. The manipulation results in cross site scripting. The attack may be performed from remote. The exploit is now public and may be used. Upgrading to version 4.10.2 is sufficient to fix this issue. You should upgrade the affected component. The vendor confirms that this is "[f]ixed in version 4.10.2". Furthermore, that "[b]ackports for older versions in process and will be out as soon as their respective CI pipelines complete."

Risk Information
cvss2
Base: 5.0
Severity: LOW
AV:N/AC:L/Au:N/C:N/I:P/A:N
cvss3
Base: 4.3
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:U/C:N/I:L/A:N
cvss4
Base: 5.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:P/VC:N/VI:L/VA:N/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

MJML through 4.18.0 allows mj-include directory traversal to test file existence and (in the type="css" case) read files. NOTE: this issue exists because of an incomplete fix for CVE-2020-12827.

Risk Information
cvss3
Base: 4.5
Severity: HIGH
CVSS:3.1/AV:L/AC:H/PR:N/UI:N/S:C/C:L/I:N/A:L
Description

A half-blind Server Side Request Forgery (SSRF) vulnerability exists in kube-controller-manager when using the in-tree Portworx StorageClass. This vulnerability allows authorized users to leak arbitrary information from unprotected endpoints in the control plane’s host network (including link-local or loopback services).

Risk Information
cvss3
Base: 5.8
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:H/UI:N/S:C/C:H/I:N/A:N